Remdesivir
Treatment for Covid 19
Typical Dosage: 200 mg IV on Day 1, then 100 mg IV daily
Effectiveness
70%
Safety Score
60%
Clinical Trials
123
Participants
20K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
200 mg IV on Day 1, then 100 mg IV daily
Time to Effect
5-10 days
Treatment Duration
3-5 days
Evidence Quality
HIGHNumber Needed to Treat (NNT)
11(Treat 11 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
200(Treat 200 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$2,300
Monitoring:$100
Side Effect Mgmt:$50
Total Annual:$2,450
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$19,500/QALY
QALYs Gained
0.01
Outcome-Based Costs
Cost per Responder
$4,454.55
Comparison vs Supportive care
Cost Difference
+$1,500/year
More expensive
QALY Difference
+0.01 QALYs
Better outcomes
Dominance
No dominance
Remdesivir Outcomes
for Covid 19
Efficacy Outcomes
Overall Effectiveness
+70%
Response Rate
+55%
Common Side Effects
Nausea
+12%
Elevated liver enzymes (ALT/AST)
+7%
Infusion-related reactions
+2%
Renal impairment
+1%
Active Clinical Trials
3 active trials recruiting for Remdesivir in Covid 19
A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised
NCT07013474RECRUITINGPHASE3
300 participants
INTERVENTIONAL
Canoga Park, United States +100 more
Started: Jul 14, 2025
Safety and Effectiveness of a Remdesivir Treatment to Prevent Severe COVID-19 in Kidney Transplant Patients
NCT07197164RECRUITINGPHASE2
15 participants
INTERVENTIONAL
Badalona, Spain
Started: Sep 1, 2025
Evaluation of Direct Antiviral Treatments Against SARS-CoV-2 in Immunocompromised Patients With Covid-19. A G2i Study, National Multicenter Observational and Retrospective From June 2023 to April 2024
NCT06683937NOT YET RECRUITING
300 participants
OBSERVATIONAL
Angers, France +15 more
Started: Dec 1, 2025
Completed Clinical Trials
7 completed trials for Remdesivir in Covid 19
An Open-label, Clinical Feasibility Study of the Efficacy of Remdesivir for Long-COVID.
NCT05911906COMPLETEDPHASE4
73 participants
INTERVENTIONAL
Derby, United Kingdom +3 more
Started: Oct 8, 2024
Efficacy and Safety of Remdesivir and Tociluzumab for the Management of Severe COVID-19: A Randomized Controlled Trial
NCT04678739COMPLETEDPHASE3
205 participants
INTERVENTIONAL
Chittagong, Bangladesh +3 more
Started: Aug 15, 2020
Study of Remdesivir in Participants Below 18 Years Old With COVID-19
NCT04431453COMPLETEDPHASE2, PHASE3
59 participants
INTERVENTIONAL
Birmingham, United States +31 more
Started: Jul 21, 2020
Study to Evaluate the Clinical Outcomes in Adults With Covid-19 Who Have Been Treated With Remdesivir.
NCT04847622COMPLETED
451 participants
OBSERVATIONAL
Nantes, France +11 more
Started: Feb 12, 2021
Multicenter, Retrospective Study of the Effects of Remdesivir in the Treatment of Severe Covid-19 Infections
NCT04365725COMPLETED
84 participants
OBSERVATIONAL
Paris, France
Started: May 5, 2020
Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)
NCT06729593COMPLETEDPHASE3
87 participants
INTERVENTIONAL
Tucson, United States +39 more
Started: Apr 20, 2021
PK and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the US
NCT04582266COMPLETED
54 participants
OBSERVATIONAL
Los Angeles, United States +9 more
Started: Mar 31, 2021
Showing 20 of 123 total trials